Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin
Background Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. Here, we explore whether immunogenic cell death (I...
Saved in:
Main Authors: | Jichao Sun, Dinglan Wu, Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Chengchao Xu, Zhijie Li, Jigang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/7/e008888.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy
by: Fatemeh Dehghan, et al.
Published: (2025-02-01) -
Exosomes and their distinct integrins transfer the characteristics of oxaliplatin- and 5-FU-resistant behaviors in colorectal cancer cells
by: Zeynab Vakili-Ghartavol, et al.
Published: (2025-02-01) -
Regulation of NK cell development, maturation, and antitumor responses by the nuclear receptor NR2F6
by: Johannes Woelk, et al.
Published: (2025-02-01) -
Construction and validation of a prognostic model for NK/T-cell lymphoma based on random survival forest algorithm
by: HUANG Zhen, et al.
Published: (2025-02-01) -
2018 icd-10-PCS /
by: Buck,Catol J.
Published: (2018)